Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9833459 | FRESENIUS KABI USA | Fulvestrant formulations |
Feb, 2034
(11 years from now) | |
US10188663 | FRESENIUS KABI USA | Fulvestrant formulations |
Feb, 2034
(11 years from now) | |
US9271990 | FRESENIUS KABI USA | Fulvestrant formulations |
May, 2034
(11 years from now) |
Market Authorisation Date: 20 May, 2019
Treatment: Treatment of hormone receptor positive advanced breast cancer in postmenopausal women
Dosage: SOLUTION;INTRAMUSCULAR
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic